Articles related to GUIDELINES/RECOMMENDATIONS

On April 25, 2023, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2023 clinical practice guideline amendment for the management of advanced prostate cancer. This guideline contains a total of 40 recommendations, and the revision includes updates to recommendations under these disease states:

In the first update in more than five years, these new guidelines review dosing recommendations for 41 antimicrobials, as applicable for patients with a BMI greater than or equal to 30 kg/m.

Check out the updated guideline for changes prevention and treatment of VTE in a variety of cancer settings.

A recent guideline update published in the Journal of Clinical Oncology offers updated recommendations for managing noncastrate advanced, recurrent, or metastatic prostate cancer. The authors recommend five separate standards of care, including docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide, all administered with androgen deprivation therapy (ADT). Triplet therapy is superior to doublet therapy, and there are no recommendations for the use of any of these agents in any other combination or series apart from the triplet therapies of docetaxel plus abiraterone plus ADT and docetaxel plus darolutamide plus ADT. Docetaxel plus ADT should be offered to patients with metastatic noncastrate prostate cancer with high-volume disease who are unwilling or unable to receive triplet therapy. Triplet therapy should be offered to patients with de novo metastatic noncastrate prostate cancer with high-volume disease who are being offered ADT plus docetaxel chemotherapy, with significant overall survival and radiographic progression-free survival benefits. Overall, patients should be informed that doublet therapy (docetaxel plus ADT) has been proven inferior to triplet therapy such as abiraterone and prednisone plus docetaxel plus ADT.

The National Comprehensive Cancer Network (NCCN) Guidelines are continuously updated to reflect the latest advances in cancer treatment. New agents and combinations are introduced all the time, and NCCN guidelines are refreshed regularly to include new technologies, drugs, and approaches. The guidelines are developed and maintained by panels of experts who review the latest science, including new publications, FDA approvals, and information presented at scientific meetings. The goal is to include new information that has been sufficiently validated to provide clinical utility and benefit to patients. In-person interactions at the NCCN conference are essential to the exchange of ideas and the creation of relationships that lead to shared learning and collaboration. The NCCN plans to continue evolving and adapting to the changing landscape of cancer care by keeping up with the latest data and by focusing on inclusiveness, equity, and access. The organization aims to expand access to traditionally marginalized and underserved populations and to reach out to communities through their trusted sources. The NCCN is committed to learning from patients and communities to ensure that everyone benefits from advances in cancer treatment.

The American Optometric Association (AOA) has released a revised clinical practice guideline to help doctors of optometry provide comprehensive eye and vision exams for adults. The guideline was created due to the significant public and economic impact of increasing visual impairments, blindness, and an aging population in the United States. The guideline recommends annual comprehensive eye exams for adults aged 18-64 to optimize visual function, detect sight-threatening eye and systemic health conditions early, and prevent or reduce vision loss. The guideline emphasizes that early detection of eye and vision problems can improve a patient’s visual function and quality of life.